Swiss National Bank Phathom Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$137 Billion
Q1 2025

A detailed history of Swiss National Bank transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 73,300 shares of PHAT stock, worth $298,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,300

Previous 73,300 -0.0%

Holding current value

$298,331

Previous $595,000 22.86%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$10.25 - $19.5 $177,325 - $337,350	17,300 Added 30.89%	73,300 $1.33 Million
Q4 2023 Feb 06, 2024	SELL	$6.99 - $10.71 $29,358 - $44,982	-4,200 Reduced 6.98%	56,000 $511,000
Q3 2023 Nov 08, 2023	SELL	$10.26 - $15.7 $115,938 - $177,410	-11,300 Reduced 15.8%	60,200 $624,000
Q2 2023 Aug 09, 2023	BUY	$7.28 - $14.32 $226,408 - $445,352	31,100 Added 76.98%	71,500 $1.02 Million
Q1 2023 May 10, 2023	SELL	$6.19 - $12.36 $6,809 - $13,596	-1,100 Reduced 2.65%	40,400 $288,000
Q2 2022 Aug 09, 2022	BUY	$6.2 - $15.5 $50,220 - $125,550	8,100 Added 24.25%	41,500 $350,000
Q1 2022 May 09, 2022	BUY	$11.55 - $20.06 $27,720 - $48,144	2,400 Added 7.74%	33,400 $455,000
Q2 2021 Aug 06, 2021	BUY	$32.66 - $39.87 $470,303 - $574,128	14,400 Added 86.75%	31,000 $1.05 Million
Q1 2021 May 07, 2021	BUY	$33.86 - $48.68 $16,930 - $24,340	500 Added 3.11%	16,600 $623,000
Q2 2020 Aug 05, 2020	BUY	$25.06 - $54.6 $403,466 - $879,060	16,100 New	16,100 $530,000

Others Institutions Holding PHAT

# of Institutions

152

Shares Held

66.6M

Call Options Held

94K

Put Options Held

55.5K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $159M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Phathom Pharmaceuticals, Inc. Transaction History